glp-1 drugs market dynamics 2025 Agonists Report 2025-2033, By Product, Molecule, and Geo Obesity GLP-1 Market
Description
Research & Innovation Disclosure STAAR LABS collaborates with clinics, pharmacies, and healthcare professionals to advance innovation in real-world metabolic health protocols
The first GLP-1 drug was called Byetta or exenatide, and FDA officials approved it in 2006
As Prime Therapeutics observed: "This real-world study finds that persistence and adherence to these products is substantially lower than what has been reported in clinical trials"
The link to AD was previously implicated through its association with T2DM, where insulin receptors and signaling were found to be similarly desensitized between both conditions [59]
